The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 10, 2024

Filed:

Jul. 30, 2020
Applicants:

The Trustees of Dartmouth College, Hanover, NH (US);

King's College London, London, GB;

Inventors:

Randolph J. Noelle, Plainfield, NH (US);

Sabrina Ceeraz, Lebanon, NH (US);

Isabelle LeMercier, Enfield, NH (US);

Elizabeth Nowak, West Lebanon, NH (US);

Janet Lines, London, GB;

Assignees:
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07K 14/705 (2006.01); A01K 67/0276 (2024.01); A61K 38/17 (2006.01); A61K 39/39 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); C07K 16/18 (2006.01); C07K 16/28 (2006.01); C07K 19/00 (2006.01); C12N 15/00 (2006.01); C12N 15/113 (2010.01); A61K 38/00 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/18 (2013.01); A01K 67/0276 (2013.01); A61K 39/39 (2013.01); A61K 39/395 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); C07K 14/70503 (2013.01); C07K 14/70532 (2013.01); C07K 16/2827 (2013.01); C12N 15/1138 (2013.01); A01K 2217/075 (2013.01); A01K 2227/105 (2013.01); A01K 2267/0325 (2013.01); A01K 2267/0368 (2013.01); A01K 2267/0387 (2013.01); A61K 38/00 (2013.01); A61K 2039/505 (2013.01); C07K 2317/76 (2013.01); C07K 2319/30 (2013.01); C07K 2319/32 (2013.01); C07K 2319/735 (2013.01); C12N 2310/14 (2013.01);
Abstract

The present invention relates to a fusion proteins comprising regulatory T cell protein, VISTA (V-domain Immunoglobulin Suppressor of T cell Activation (PD-L3) and an immunoglobulin protein (Ig), preferably also containing a flexible linker intervening the VISTA and Ig Fc polypeptide. The invention also provides the use of VISTA polypeptides, multimeric VISTA polypeptides, VISTA-conjugates (e.g., VISTA-Ig), and VISTA antagonists for the treatment of autoimmune disease, allergy, and inflammatory conditions, especially lupus, multiple sclerosis, psoriasis, psoriatic arthritis, multiple sclerosis, Crohn's disease, inflammatory bowel disease and type 1 or type 2 diabetes.


Find Patent Forward Citations

Loading…